Alzheimer's Enzyme BACE1 Cuts Anti-Aging Protein Klotho: A New Link Between Aging and Cognitive Decline

The Alzheimer's-associated enzyme BACE1 was found to cleave the anti-aging protein α-Klotho at a specific peptide site, revealing a potential shared pathway linking aging to cognitive decline.

Gao, Xiang et al.·Journal of Alzheimer's disease : JAD·2025·
RPEP-110392025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

BACE1 was identified as an enzyme that cleaves α-Klotho peptide 951-981 at the F-T residues, confirmed by Coomassie blue staining, western blot, and MALDI-TOF mass spectrometry. When F-T was mutated to K-K, BACE1 could not cleave the peptide, confirming site specificity. Plasma α-Klotho was significantly lower in elderly vs. young participants (p<0.0001). In elderly adults, BACE1 and α-Klotho showed a significant positive correlation (p=0.009, r=0.469) not seen in young adults (p=0.170, r=-0.208), suggesting the BACE1/α-Klotho pathway becomes functionally relevant with aging.

Key Numbers

How They Did This

The study recruited 30 elderly and 45 young participants. Researchers performed in vitro enzymatic digestion of α-Klotho peptide by BACE1, identifying cleavage products using Coomassie blue staining, western blot, and MALDI-TOF mass spectrometry. Site-directed mutagenesis confirmed the cleavage site. Plasma levels of both proteins were measured by ELISA, and correlations were analyzed between age groups.

Why This Research Matters

α-Klotho is one of the most studied anti-aging proteins, and BACE1 is a major therapeutic target in Alzheimer's research. Discovering that BACE1 directly cleaves α-Klotho creates a new mechanistic link between aging and neurodegeneration. This could explain why α-Klotho levels drop with age and suggests that BACE1 inhibitors — already being developed for Alzheimer's — might also preserve α-Klotho levels and potentially slow aging.

The Bigger Picture

BACE1 inhibitors have been a major focus of Alzheimer's drug development, though clinical trials have had mixed results. This discovery that BACE1 also degrades α-Klotho adds a new dimension: BACE1 may contribute to aging beyond its known role in amyloid-beta production. The BACE1/α-Klotho axis could represent a common pathway for age-related cognitive decline, opening new angles for both aging and Alzheimer's research.

What This Study Doesn't Tell Us

The enzymatic cleavage was demonstrated in vitro, and it remains to be confirmed that this cleavage occurs at physiologically relevant rates in vivo. The human cohort (75 participants) is relatively small for correlation analyses. The positive correlation between BACE1 and α-Klotho in elderly adults is counterintuitive if BACE1 degrades α-Klotho, suggesting more complex regulatory dynamics that need investigation.

Questions This Raises

  • ?Would BACE1 inhibitors preserve α-Klotho levels in vivo and slow age-related cognitive decline?
  • ?Does the BACE1/α-Klotho cleavage pathway contribute to cognitive decline independently of amyloid-beta production?
  • ?Why are BACE1 and α-Klotho positively correlated in elderly adults if BACE1 cleaves α-Klotho?

Trust & Context

Key Stat:
Specific Cleavage at F-T Residues BACE1 cleaves α-Klotho peptide 951-981 at the F-T site — a newly discovered enzymatic relationship linking the most studied Alzheimer's enzyme to the best-known anti-aging protein
Evidence Grade:
This is an original research study combining in vitro biochemistry with human plasma analysis. The enzymatic cleavage is well-demonstrated with multiple validation methods, though the clinical significance of this pathway needs confirmation in larger studies and in vivo models.
Study Age:
Published in 2025, this study presents a novel discovery linking two of the most actively researched proteins in aging and Alzheimer's disease.
Original Title:
Identification of the enzymatic cleavage relationship between anti-aging protein α-Klotho and Alzheimer's disease biomarker BACE1.
Published In:
Journal of Alzheimer's disease : JAD, 104(2), 463-472 (2025)
Database ID:
RPEP-11039

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is α-Klotho and why is it called an anti-aging protein?

α-Klotho is a protein that declines with age and is associated with longevity. Animals with more α-Klotho tend to live longer and have better cognitive function, while deficiency accelerates aging. This study found that the Alzheimer's enzyme BACE1 can break down α-Klotho, potentially explaining why its levels drop as we age.

Could Alzheimer's drugs help slow aging?

Potentially. BACE1 inhibitors are being developed to reduce amyloid-beta production in Alzheimer's patients. This study suggests these same drugs might also preserve α-Klotho levels, which could provide additional anti-aging benefits — though this hypothesis needs further testing.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-11039·https://rethinkpeptides.com/research/RPEP-11039

APA

Gao, Xiang; Sun, Zuoli; Hu, Jia; Li, Yuhong; Deng, Qi; Li, Rena. (2025). Identification of the enzymatic cleavage relationship between anti-aging protein α-Klotho and Alzheimer's disease biomarker BACE1.. Journal of Alzheimer's disease : JAD, 104(2), 463-472. https://doi.org/10.1177/13872877251317730

MLA

Gao, Xiang, et al. "Identification of the enzymatic cleavage relationship between anti-aging protein α-Klotho and Alzheimer's disease biomarker BACE1.." Journal of Alzheimer's disease : JAD, 2025. https://doi.org/10.1177/13872877251317730

RethinkPeptides

RethinkPeptides Research Database. "Identification of the enzymatic cleavage relationship betwee..." RPEP-11039. Retrieved from https://rethinkpeptides.com/research/gao-2025-identification-of-the-enzymatic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.